Patient selection
Patients age > 18 at the time of rHGG diagnosis (WHO
grade IV GBM or WHO grade III anaplastic astrocytoma) treated with
concurrent ICI+SBRT or ICI monotherapy at New York-Presbyterian Hospital
between 1/1/16 to 1/1/19 were included for analysis. This study was
approved by the Weill Cornell Medicine Institutional Review Board.
Demographic data, tumor pathological characteristics and profiling from
available Foundation studies, radiology variables (tumor size,
perfusion/diffusion metrics, and RT necrosis), prior treatments, AE’s
attributable to treatment, PFS and OS following concurrent ICI + SBRT
were collected. Survival data was obtained from available medical
records.